INTRODUCTION

Morbid obesity and Diabetes
Obesity has become one of the greatest public health challenges in the 21st century, with an epidemic prospect that > 50% of the world's adult population will be overweight and obese by 2030 1 . Of special interest in this context is diabetes -the most expensive co-morbidity; a disease which in 80% is associated with overweight 2 . Bariatric surgery is currently the only effective treatment for morbid obesity and its co-morbidities, especially diabetes [3] [4] [5] . Improvement of glucose metabolism after bariatric surgery is impressive, as we could show in our own prospective trials 6 . Though there are some hypotheses how glucose metabolism ameliorates early after surgery (before weight-loss occurs), the exact mechanisms are not known. One of our on-going studies comparing morbidly obese non-diabetic to diabetic patients before and after surgery suggest that the mechanism underlying glucose intolerance in these two groups is not the same (Wölnerhanssen et al, unpublished data). Studies in this field can help to better understand the mechanisms of diabetes in general and in the morbidly obese in particular.
The pathophysiological background of morbid obesity is not yet clear, nor is the physiology behind appetite, satiety regulation and weight-maintenance fully understood. Surgery has been proven to be effective in terms of weight-loss and reduction in co-morbidities. However, the exact mechanisms underlying different bariatric procedures are yet unknown. Progress in treatment other than surgery critically depends on high-quality clinical research in this field. At least theoretically, knowing more about morbid obesity and mechanisms of bariatric surgery could lead to interesting targets for treatment regimens in the future. Morbidly obese patients treated by different bariatric procedures with different anatomical changes of the GI-tract offer a great opportunity to study the pathophysiology behind morbid obesity.
Satiety system: gut hormones
Various gut hormones regulate food intake and some even show direct effects on glucose metabolism. One promising approach is the development of drugs based on gastrointestinal (GI) satiety peptides such as glucagon-like peptide-1 (GLP-1). Its anorectic action is of great clinical interest as the eating-inhibitory effect is not only seen in healthy subjects, but is preserved in obese and/or diabetic persons [7] [8] [9] . Understanding the exact mechanisms by which GLP-1 inhibits eating is crucial in order to convert its anorectic action into useful, safe and effective drugs. After eating, the brain senses a biochemical change and then signals satiation, but the precise sequence of events has not yet been determined. Even for established physiological systems like glucose-insulin regulation, the timing of interaction between hormonal processes and neural events is inferred mostly from blood sampling studies. Recently, neuro-imaging studies have provided in vivo information about the neuro-anatomical correlates of the regulation of energy intake. Temporal orchestration of such systems is, however, crucial to the integration of neural and hormonal signals that control eating behavior. In a landmark paper demonstrating eating-related neural activity in the brain, the response was interacting with an internal signal, the plasma insulin. Oral glucose is a potent stimulant for insulin release modified by the incretin hormone GLP-1. Furthermore exogenous administration of GLP-1 to healthy humans or to diabetic patients dose-dependently reduces food intake and induces satiety suggesting that the peptide could be one of the gut players interacting with the brain 10, 11 . Healthy, normal-weight people show a postprandial peak of GLP-1 secretion after 15-30 min. In contrast in morbidly obese patients, postprandial GLP-1 secretion is blunted. After bariatric surgery, dynamics of GLP-1 secretion are restored 12 .
In mice, functional MRI after GLP-1 administration showed reduced signal intensity in the targets PVN (paraventricular nucleus) and VMH (ventromedial hypothalamus) 13, 14 In humans, functional MRI in correlation with GLP-1 levels has recently been carried out on healthy volunteers at the Imperial College of London: Infusion of GLP-1 led to reduction of brain activity across all selected ROI's (regions of interest), the greatest change seen in the right insula 15 . Thus, the GLP-1 targets in the human brain are known. However, so far studies on morbidly obese before and after surgery have not yet been carried out. This offers an excellent possibility to investigate neuro-anatomical correlates of the regulation of food intake and examine gut-brain signaling, with special focus on the obese. The results of our recent studies document that glucose as well as fatty acids are both potent secretagogues for GLP-1 secretion, whereas artificial sweeteners do not induce a GLP-1 response. The effect is most likely mediated in large part by a heterodimeric sweet taste receptor, T1R2/T1R3. Lactisole©, a broad-acting sweet taste receptor antagonist, suppresses the sweet taste of sugars, protein sweeteners, and artificial sweeteners in vitro 16 and has been approved for use in food as flavoring agent. Due to its inhibitory effects on the sweet receptor, lactisole is an excellent tool to better understand the regulatory role of this receptor in the control of glucose metabolism.
Taste receptors
Enteroendocrine cells (EECs) in gut villi are highly specific cells, which in total, constitute the largest endocrine organ. They release a series of hormones including cholecystokinin (I-cells), ghrelin (X-cells), gastrin (G-cells), glucose-dependent-insulinotropic peptide (GIP) (K-cells), glucagon-like peptides (GLPs) and peptide YY (PYY) (L-cells) 17, 18 . The products are released from secretory granules into the extracellular fluids to enter the circulation to act on distant targets or to interact locally with intrinsic and extrinsic (predominantly vagal) afferent neurons 19, 20 . In recent years, it has been speculated that taste receptors like those known from the tongue might be involved in the receptive function within the intestine 21, 22 . In fact, in 1996, taste receptor-like cells were first identified in the rat gut by the expression of α-gustducin 23 . Subsequent studies demonstrated the presence of several nutrient responsive G-protein-coupled receptors (GPCRs) for bitter taste (T2Rs) and amino acid, umami and sweet taste (T1Rs) both in human and rodent gut, including distribution and colocalization with L-cells expressing GLP-1 or PYY [24] [25] [26] [27] . In addition, studies in mice using knockout models for α-gustducin (α -gust-/-) or T1R3 (T1R3-/-) (part of the sweet-responsive heterodimer T1R2/T1R3) revealed deficiencies in glucose-stimulated secretion of GLP-1, and the regulation of plasma insulin and glucose 28 . Moreover, both carbohydrate sugars and artificial sweeteners were capable of stimulating the secretion of GLP-1 from EEC lines, and specific sweet taste receptor antagonists (lactisole or gurmarin) blocked the secretion of artificial sweetener-stimulated gut peptide secretion 28, 29 . Taken together, these data provide extensive evidence for the involvement of α-gustducin-coupled taste receptors in nutrient-stimulated peptide secretion. Although these basic chemosensory mechanisms have been demonstrated in several in vitro and animal studies, human data are still sparse. Recently, we were able to show co-localization of T1R3 and α-gustducin with GLP-1 in human duodenal and colonic biopsy specimens using immunohistochemistry 30 . By use of quantitative real time RT-PCR (qPCR) we could show, that the level of mRNA-expression was equally distributed in all gut segments for T1R3; in contrast α-gustducin was found to be expressed predominately in the duodenum 30 . However, these data were obtained from healthy, normal-weight patients and unfortunately stomach tissue was not involved.
HYPOTHESES
 Obesity is associated with changes in taste reception, especially desensitization of sweet reception and probably altered perception of umami. We expect to see these differences: a) on the level of the central nervous system by means of fMRI (decreased brain activation after glucose administration in the obese), b) on the level of taste receptors in gastric and intestinal tissue (e.g. decreased number of T1R3) as well as c) on the level of hormonal release (e.g. decreased GLP-1 release after glucose stimulation).
 Bariatric surgery leads to changes in gastrointestinal motility, depending on the chosen type of procedure (bypass vs. sleeve gastrectomy).
AIMS
The molecular and cellular mechanism(s) by which the biochemical composition of ingested nutrients are sensed within the intestinal lumen by enteroendocrine cells, the signaling pathways to the CNS, and the factors that modulate food intake, are poorly defined. The key ideas of this proposal are based upon world leading current neuro-imaging work in Basel that has started to map out the matrix of activation of the central nervous system upon activation of these neuro-endocrine pathways. The aim of this project is to learn more about the physiology of appetite and satiety regulation in humans by examining healthy volunteers and to correlate these findings with data from morbidly patients in order to better understand the pathophysiology behind morbid obesity. Pre-and postoperative studies will help to better understand mechanism(s) underlying bariatric procedures.
Key questions are:
1) Enlighten the gut brain axis 2) Describe interactions of different substrates on brain activity and gut hormones 3) Clarify effects of bariatric surgery on hepatic and pancreatic fat distribution
GENERAL CONSIDERATIONS Physical health
All subjects will be examined by a research physician. Basic health will be ensured by general medical examination including medical history, physical examination and blood chemistry and hematology. Anthropometric measurements including weight, height, body mass index (BMI), as well as heart rate and blood pressure will be recorded for all participants.
Informed consent
All subjects will be informed about the study they participate in, both verbally and by the approved written consent form regarding study procedures. The investigator and the subject will both personally sign and date the consent form as confirmation of consent. All studies will be approved by the Ethics Committee of the University of Basel Participation is voluntary. Participants do not profit directly from the studies.
Ethical Standards
All studies will be performed in accordance with the Declaration of Helsinki, International Conference on Harmonization, Guidelines for Good Clinical Practice (GCP) and standard operating procedures of the CRC/CTU of the University Hospital of Basel. Trained study personnel will place tubes and venous accesses, administer the perfusions and collect blood samples. Subjects will be supervised by trained study personnel during the entire test sessions, backed-up by study physicians. All studies will be done in the Phase 1 Research Unit of the University Hospital. To make sure that quality requirements are fulfilled, the Ethical Committee is empowered to audit our institution.
Data protection
All information will be treated in confidence. At any time, participants have the right to gain access to their results. All data is anonymized. For control purposes the Ethical Committee and the authorities can request to undertake inspections and gain access to original data. Biopsies will only be used for the described study and after that any tissue remnants will be destroyed (no biobank will be established).
Insurance
Subjects will be insured for this trial by Gerlach Insurance group via the University Hospital. The principle investigator will be responsible for the initiation of all necessary action in the case of harm to a subject. Studies carried out at St. Claraspital will be insured via their insurance partner.
Functional MRI after fructose and glucose-stimulation in morbidly obese patients Background
Fructose is a monosaccharide naturally found in honey, flowers and fruits. High-fructose corn syrup (HFCS) is a mixture of glucose and fructose and is found in many soft drinks. Fructose is believed to have adversary effects on diabetes and weight gain 31 . A fructose-enriched diet might lead to insulin resistance and obesity and therefore increase in fructose consumption is seen as a risk factor for metabolic syndrome 32 . Glucose is the only potent secretagogue of the release of satiety peptides such as GLP-1, PYY and inhibitor of ghrelin. In contrast, fructose infusion in healthy, normal-weight subjects doesn't affect plasma concentrations of the above mentioned peptides to the same extent as equisweet loads of glucose 16 . Nevertheless, fructose leads to prolonged satiety 16 . The pathway leading to satiety must be different from the known pathway of glucose. In rat experiments, obese rats were more interested in fructose than lean controls (preference for higher concentration) and after gastric bypass increased lick responses were alleviated 33 . There are no studies describing fructose effects on gut hormones, satiety and central effects before and after bariatric surgery in humans. In previous studies, 50-75g of glucose showed reliable GLP-1 release and brain activation. For fructose, no such data exists.
Ongoing study: From March 2012 till November 2012 we are examining 12 healthy, normal-weight volunteers by functional MRI and intragastric administration of a glucose solution with or without the sweet taste receptor blocker lactisole© , 25g fructose and 75g glucose with the GLP-1 antagonist exendin 9-39 in collaboration with Prof. S. Borgwardt. This offers an excellent possibility to investigate the neuro-anatomical correlates of the regulation of food intake and examine gut-brain signaling in healthy subjects. We believe that glucose in the gut affects the brain by means of a cascade, which is triggered by sweet taste receptor activation and mediated by the vagus nerve. The sweet taste receptor blocker Lactisole© is expected to attenuate this effect, as will exendin 9-39 as a competitive GLP-1 antagonist. In addition, we will measure brain activity after fructose administration in order to compare findings to activity after glucose ingestion.
Hypotheses
1)
In morbidly obese patients glucose is less potent to trigger the gut-brain axis than in healthy normalweight population.
2) Intragastric administration of glucose and fructose has different effects on brain activity; fructose must have an alternative way of leading to satiety.
Methods
Study design
fMR after fructose and glucose-stimulation in morbidly obese patients: The study will be conducted as a placebo-controlled trial with each subject studied on 3 occasions. The test trials will be identical in design except for the intragastral perfusions (glucose 75g, fructose 25g or placebo).
Fructose and glucose will be dissolved in 300ml tap water. The order will be balanced and pseudo-random. Each subject will participate in three 1.5 hour study sessions.
Study duration and study site
The study will preferably start in October, 2013. The study duration is then depending on MR-capacity. Between the sessions patients will have 3-5 days off. 
Recruitment and Screening
Twelve morbidly obese subjects will be recruited. Drop-outs will be replaced. The screening procedure will include the following assessments: a medical interview and a full physical examination. Anthropometric measurements including weight, height, BMI, as well as heart rate and blood pressure will be recorded for all participants. 
Inclusion criteria
Study protocol Overall design
Subjects take part in a 30 min screening session, three ~1.5 h test sessions, and a 30 min end of study (EOS) visit. During the test sessions, subjects will receive an intragastral administration of glucose, fructose or tap water (negative control). The test sessions will be identical in design except for the perfusions. The study will be performed as a randomized, double-blind, placebo-controlled, crossover study, with each subject studied on 3 occasions at least three to five days apart.
Experimental procedure
Each of the test sessions will last ~1.5 h starting at 8:00 AM resp. 9:00 AM. On each experimental session, subjects will be admitted to the Phase 1 Research Unit of the University Hospital Basel in the morning after an overnight fast and will swallow a feeding tube (external diameter 8 french). The tube will be inserted through one of the nostrils into the stomach using a guide wire. The guide wire will be removed and the tube will be firmly attached to the skin behind the ear to prevent further progression of the tube during the treatment. An intravenous catheter will be placed into one forearm. Blood will be drawn for plasma hormone measurements from at 15 or 30 minutes intervals until the end of the study (t = 60 min). Subjects will receive in random order intragastral glucose, fructose or tap water. After administration of the test solution, the feeding tube will immediately be removed and the patient will be placed on the MRI-table. A 3.0 Tesla scanner at the University Hospital of Basel will be used to acquire the neuroimaging data. First, a structural scan will be collected during 6 minutes. Then, functional MR images demonstrating brain activity will be acquired using single shot gradient echo EPI sequence with an echo time of 40ms. Image acquisition will continue for 1 hour after test solution administration. In total, four blood samples will be taken: 2 before administration of test solution, one blood sample after 15 minutes and a last blood sample at 60 min. At each time point, 10 ml blood will be taken into tubes containing EDTA (6 µmol/l), aprotinin (500 kIU/l) and a DPP-IV inhibitor. After centrifugation (3000 rpm, 10 min, 4 °C), plasma samples will be kept frozen at -20°C until analysis. Glucose, insulin, GIP, GLP-1, PYY and ghrelin will be measured. The total blood volume taken during one test day will be 40 ml.
Data Analysis, sample size estimation, statistical analysis of outcomes
The purpose of this study is to gain basic information on brain activity after administration of different carbohydrate solutions and the physiologic regulation of hormone release. Since there is no information available of effect size, sample size of this study was chosen on the basis of practical considerations rather than statistical estimation. However, according to our previous experience with intragastral stimulation of gut hormone release and brain activation, a sample size of 12 subjects will most likely allow to detect large differences between the treatment groups. Descriptive statistics will be used for demographic variables such as age, weight, height, and BMI. Individual hormone concentrations versus time data will be used to obtain GLP -1, PYY, insulin and ghrelin metrics, including maximum/minimum plasma concentrations (Cmax/Cmin), the time of maximal/minimal peptide occurrence (Tmax/Tmin) and the area under the plasma concentration-time profile (AUC). Pharmacokinetic parameters (Cmax, tmax, AUC, etc.) will be obtained using PK Functions for Excel®. AUC values will be calculated by the trapezoidal rule. Differences between treatments will be assessed using either the non-parametric Friedman-test (in case of significant differences followed by pairwise comparison using the Wilcoxon signed ranks test and Bonferroni's correction to account for multiple of comparisons); or the General linear model procedure of repeated-measures ANOVA using simple contrast and Bonferroni correction of P values for multiplicity of comparison. VAS will be analysed by calculating AUC and return to baseline values (interception with y-axis using linear interpolation). Differences will be assessed using the non-parametric Friedman-test or the General linear model procedure of repeated-measures ANOVA.
Transformations will be performed before analysis, if response variables are non-normally distributed. All statistical analysis will be done using SPSS for windows software (version 19.0).
Risks and benefits
Participants do not profit directly from this study. MRI is a non-invasive method, with no exposure to radiation.
Compensation
Subjects will receive a financial compensation of 150 CHF for each study day (for the completed trial 450 CHF). Pro rata payments will be done for early discontinuation. 
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